S. 1818: Prescription Drug Price Relief Act of 2025

S. 1818 is a federal bill in the 119th Congress. Currently, pharmaceutical companies hold exclusive rights to sell certain brand-name drugs, preventing cheaper generic alternatives from entering the market and keeping prices high. Under this bill, the Department of Health and Human Services will review… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.